VANCOUVER, British Columbia, June 11, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global CBD
innovator specializing in hemp based health and wellness products, the development of pharmaceutical CBD delivery methods and the
manufacturing of a pure, natural CBD as an Active Pharmaceutical Ingredient (API) for use in finished pharmaceutical products
(FPPs), announces unaudited May 2018 consolidated revenue numbers of $3,316,646 CDN.
Marcos Agramont, CEO of Isodiol, stated, “May was a historic month for revenues. These numbers legitimize what we have
accomplished over the last several months, particularly with the acquisitions of KURE Corp and BSPG Laboratories, Ltd. Shareholders
can expect audited financials for the period of April 1, 2017 - March 31, 2018 to be available on July 30th, 2018.”
The company has officially opened its new Corporate Headquarters at 2710 – 200 Granville St., Vancouver, BC V6C 1S4. The new
location will allow the company to continue to grow its management team and to focus on Canadian sales and expansion as cannabis
laws continue to positively change within Canada.
Two of the company’s flagship medical products, Isoderm and Purodiol, were recently featured at the International League Against
Epilepsy in Sao Paola, Brazil. The congress was hosted by neurology experts from around the world. “As the company continues to
expand its international footprint, it is crucial that we stay at the forefront of these conferences and educate the medical
community about our approved deliveries of CBD and the recent approval of our API for use in finished pharmaceutical products, said
Agramont.”
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade pure,
natural CBD and the industry leader in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts in the CBD industry, including the commercialization of 99%+ pure, natural
isolated CBD, micro-encapsulations, and nano-technology for the highest quality consumable and topical skin care products. Most
recently, the company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished
Pharmaceutical Products as was announced April 26, 2018.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its
consumer products portfolio and aggressively continue international expansion into Latin America, Asia, and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
Forward-Looking Information: This news release contains "forward-looking
information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and
future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the
expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will
prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking
statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially
from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will
vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as
required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or
forward-looking information in this news release. Although the Company believes that the expectations reflected in the
forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no
reference to profitability based on sales reported. The statements in this news release are made as of the date of this
release.
The CSE has not reviewed, approved or disapproved the content of this press release.